SCHEMBL16635949

SCHEMBL16635949

COC(=O)C1CCCCC1c1nc(Oc2ccccc2)sc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.48
SLC6A4 P31645 3/20 0.48
CPT2 P23786 1/20 0.43
CPT1A P50416 1/20 0.43
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
TSHR P16473 3/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
SLC6A3 Q01959 2/20 0.36
CNR2 P34972 1/20 0.35
BTK Q06187 1/20 0.35
KDM4E B2RXH2 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635947 1.00 SLC6A2 (0.48) SLC6A2SLC6A4CPT2CPT1AFNTA
SCHEMBL16635762 0.89 FNTA (0.43) FNTAFNTBTSHRBTKKDM4E
SCHEMBL16635933 0.79 SLC6A2 (0.49) SLC6A2SLC6A4CPT2CPT1AFNTA
SCHEMBL16635935 0.79 SLC6A2 (0.49) SLC6A2SLC6A4CPT2CPT1AFNTA
SCHEMBL16635759 0.78 SLC6A2 (0.41) SLC6A2SLC6A4CPT2CPT1ATSHR
SCHEMBL16636094 0.76 SLC6A2 (0.42) SLC6A2SLC6A4CPT2CPT1ATSHR
SCHEMBL16636575 0.76 CTSK (0.49) SLC6A2SLC6A4CPT2CPT1AALDH1A1
SCHEMBL16636097 0.76 CTSK (0.49) SLC6A2SLC6A4CPT2CPT1AALDH1A1
SCHEMBL16636407 0.75 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1GAACNR2
SCHEMBL16636408 0.75 SLC6A2 (0.45) SLC6A2SLC6A4ALDH1A1GAACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015051479-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ SLC6A2 4308/4885SLC6A4 4386/4885CPT2 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.